Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect.
Amgen beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $9.09 billion, up 10.9% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance slightly topping analysts’ expectations.
Is Amgen a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Amgen’s revenue to grow 7.8% year on year to $8.03 billion, slowing from the 22% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.26 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amgen has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Amgen’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. AbbVie delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 3.3%, and Gilead Sciences reported flat revenue, falling short of estimates by 2.1%. AbbVie traded up 6.6% following the results while Gilead Sciences was down 2.7%.
Read our full analysis of AbbVie’s results here and Gilead Sciences’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Amgen is down 5.6% during the same time and is heading into earnings with an average analyst price target of $313.54 (compared to the current share price of $289.63).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.